Osaka, Japan, April 25, 2024 - Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) today announced that it has entered into a drug discovery collaboration agreement with PRISM BioLab (Head Office; Kanagawa, Japan; President & CEO: Dai Takehara; “PRISM') to generate novel drug candidates in the oncology area..

日本大阪，2024年4月25日-大野制药有限公司（总部：日本大阪；总裁：Toichi Takino；“大野”）今天宣布，它已与PRISM BioLab（总部；日本神奈川；总裁兼首席执行官：Dai Takehara；“PRISM”）签订药物发现合作协议，以在肿瘤学领域产生新的候选药物。。

Based on the agreement, Ono and PRISM will collaborate to identify and generate development drug candidates of a protein-protein interaction (PPI) target selected by Ono utilizing PRISM’s proprietary PepMetics® technology. Ono will acquire exclusive worldwide rights to develop and commercialize small molecule compounds generated through the collaboration.

根据该协议，Ono和PRISM将合作，利用PRISM专有的PepMetics®技术，确定并生成Ono选择的蛋白质-蛋白质相互作用（PPI）靶标的候选开发药物。小野将获得开发和商业化通过合作产生的小分子化合物的全球独家权利。

Ono will make to PRISM an upfront fee, research funding, milestone payments based on the progress of research, development and commercialization, tiered royalties based on net sales, and other terms. .

小野将向PRISM支付预付费、研究资金、基于研究、开发和商业化进展的里程碑付款、基于净销售额的分层版税以及其他条款。

“We are actively engaged in creating innovative drugs through open innovation to address unmet medical needs across a wide range of diseases,” said Seishi Katsumata, Executive Director, Discovery & Research of Ono. “We highly appreciate PRISM’s PepMetics® technology in PPI drug discovery, which we believe has potentials to identify and develop novel small molecule drugs for therapeutic targets that had been previously difficult to modulate with small molecules.

“我们积极参与通过开放式创新创造创新药物，以解决各种疾病未满足的医疗需求，”小野发现与研究执行董事Seishi Katsumata说。“我们高度赞赏PRISM在PPI药物发现中的PepMetics®技术，我们认为该技术有潜力为以前难以用小分子调节的治疗靶点鉴定和开发新型小分子药物。

We anticipate that the technology will further expand our development pipeline for innovative new drugs.”.

我们预计该技术将进一步扩大我们创新新药的开发渠道。”。

“We are very excited to enter into this collaboration with Ono Pharmaceuticals who has a history of creating innovative drugs,” said Dai Takehara, President & CEO of PRISM Biolab. “We believe that our PepMetics® technology will change the current paradigm in drug discovery by turning previously undruggable PPIs into targets readily druggable with small molecules.

PRISM Biolab总裁兼首席执行官Dai Takehara表示：“我们非常高兴能与具有创新药物开发历史的大野制药（Ono Pharmaceuticals）进行合作。”。“我们相信，我们的PepMetics®技术将改变目前药物发现的范式，将以前不可药用的PPI转化为易于用小分子药物治疗的靶标。

Through close collaboration between creative scientists of both companies, we expect to generate innovative and game-changing drugs for the benefit of patients.”.

通过两家公司的创新科学家之间的密切合作，我们期望为患者的利益生产创新和改变游戏规则的药物。”。

About PRISM BioLab

关于PRISM BioLab

PRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics® technology to discover orally available small molecule inhibitors of protein-protein interaction (PPI) targets and transform lives of patients suffering from cancer, autoimmune, fibrosis and other diseases.

PRISM BioLab是一家发现和开发生物技术公司，利用专有的PepMetics®技术发现口服可用的蛋白质-蛋白质相互作用（PPI）靶点小分子抑制剂，并改变患有癌症，自身免疫，纤维化和其他疾病的患者的生活。

PepMetics® are a unique class of small molecules that mimic three-dimensional structures of alpha-helix and beta-turn, the peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. By combining proprietary chemistry, know-how around PPI targets and AI-supported design, PepMetics® technology can deliver inhibitors of challenging PPI targets.

PepMetics®是一类独特的小分子，可模拟α-螺旋和β-转角的三维结构，这是细胞内PPI相间和受体-配体相互作用中常见的肽结构。通过结合专有化学、围绕PPI目标的专有技术和AI支持的设计，PepMetics®技术可以提供具有挑战性的PPI目标抑制剂。

The technology holds promise to expand the field of drug discovery by turning previously undruggable PPIs into targets readily druggable with small molecules and by generating oral small molecule alternatives for injectable biologics. PRISM BioLab is collaborating on new PPI targets with global and Japanese pharmaceutical companies.

该技术有望通过将以前不可治疗的PPI转化为易于用小分子药物治疗的靶标，并通过产生可注射生物制剂的口服小分子替代品来扩大药物发现领域。 PRISM BioLab正在与全球和日本制药公司合作制定新的PPI目标。

PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai Co., Ltd. and Ohara Pharmaceuticals Co., Ltd. are in clinical development for cancer and liver disease, respectively.For further information: www.prismbiolab.com .

获得卫材株式会社和大原制药株式会社许可的针对CBP/β-连环蛋白的PepMetics®PPI正在分别针对癌症和肝病进行临床开发。欲了解更多信息，请访问www.prismbiolab.com。